Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big guns see positive sales trend in first quarter

This article was originally published in Clinica

Executive Summary

CR Bard's surgical division had sales of $51 million, up 16%, above the expectations of analysts at Morgan Stanley Dean Witter. The vascular division's sales rose 5% to $61 million, in line with expectations. The company's urology, oncology and "other" divisions were below the analysts' expectations. Urology sales were $92 million, up 3%, oncology sales were up 7% to $65 million, while "other" sales were down 3% to $15 million. The company hopes to save up to $80 million in annual cost savings through various initiatives over the next four years. Baxter's earnings per share rose 9% to $0.71, in line with consensus estimates. For the full year, the company expects low double-digit sales growth with earnings in the mid-teens. In the quarter, Baxter increased its R&D expenditure by 24% to $103 million. Looking beyond 2001, the company envisages sales growth in the low to mid-teens and earnings growth in the mid- to high teens.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel